Lead Product(s) : MB-101,MB-108
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MB-109 is Mustang’s designation for the treatment regimen combining MB-101 (COH-developed IL13Rα2‐targeted CAR-T cell therapy) with MB-108 (Nationwide-developed HSV-1 oncolytic virus), which is investigated for Recurrent Glioblastoma and High-Grade ...
Product Name : MB-109
Product Type : Antibody
Upfront Cash : Inapplicable
October 26, 2023
Lead Product(s) : MB-101,MB-108
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MB-101, an IL13Rα2-targeted CAR T cell therapy demonstrate durable complete responses in GBM based on a 54-patient Phase 1 trial, as an optimized CAR T product incorporating enhancements in CAR design and T cell engineering to improve antitumor potency ...
Product Name : MB-101
Product Type : Antibody
Upfront Cash : Inapplicable
September 03, 2022
Reset All
